COSTA MESA, Calif., Feb. 23, 2015 /PRNewswire-iReach/ -- WCCT Global, a contract research organization that is known for their capability to conduct Ethnobridging clinical trials announced today their role in support of the largest Ethnobridging clinical trial ever conducted in the United States. The recently published article entitled, "Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States", characterized rosuvastatin exposure in Chinese, Filipino, Asian-Indian, Korean, Vietnamese, Japanese and Caucasian subjects. WCCT Global was responsible for recruitment and the clinical conduct for this trial. The primary objective of the study was to characterize rosuvastatin plasma exposure in subjects from several Asian regions of the world relative to Caucasians from North America.
Photo - http://photos.prnewswire.com/prnh/20150220/176872
WCCT Global conducted this clinical trial in their Cypress clinical pharmacology unit where they conduct most ethnobridging trials. The trial provided information that plasma exposure to rosuvastatin and its metabolites was significantly higher in Asian subgroups like, Chinese, Filipino, Korean, Vietnamese and Japanese residing in the USA compared with Caucasian subjects also residing in the US. Interestingly, exposure in Asian-Indians was higher than in Caucasians but lower than in the "pooled" Asian group. WCCT Global's CEO Dr. Kenneth Kim stated, "the study was a large success and WCCT Global was pleased to be an integral part in progressing the understanding of ethno-sensitivity in drug exposure. "I think that the outcome of this trial is of paramount importance because it clearly demonstrates that if drug exposure is intrinsically different between populations from different geographic regions of the world it can be detected in a single trial in a single region which includes those ethnic groups of interest. We at WCCT Global take pride in educating the members of the diverse ethnic communities near our locations about clinical trials and the importance of participation in clinical research. We focus on making sure that all our volunteers have a clear understanding of what a clinical trial is about and hope that they enjoy every aspect of their stay with us while participating in clinical research."
More about WCCT Global:
WCCT Global is a multi-site, full service global contract research organization (CRO) of outsourced early drug development and late phase services to the pharmaceutical, biotechnology and medical device industries. The WCCT Global vision, "With compassion for people, we strive for tomorrow's therapies to be available today" truly exemplifies the focus and reason for our cutting edge work both in our clinics and throughout our operations. As a drug development partner, WCCT Global collaborates with domestic and foreign innovator companies who need regulatory, program management, data management and strategic consulting support, with an emphasis on overseeing and executing trials in special disease populations, pediatric populations, ethno-bridging, and cardiac safety. WCCT has extensive experience with healthy volunteer studies including First-in-Human (FIH), as well as specific therapeutic expertise in Allergy, Asthma, HCV, Ophthalmology, Oncology, Renal, and Vaccines.
Media Contact:Matt Miller, WCCT Global, 714.668.1500 ext.2029, Matt.Miller@wcct.com
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE WCCT Global
Help employers find you! Check out all the jobs and post your resume.
